ortataxel (BAY 59-8862) / Assertio - LARVOL DELTA

Molecular docking analysis of docetaxel analogues as duel lipocalin 2 inhibitors. (PubMed, Bioinformation) - "We document 10 analogues (4Deacetyltaxol, 7Acetyltaxol, Cabazitaxel, Cephalomannine, Docetaxal, Deacetyltaxol, Docetaxeltrihydrate, Ortataxel, Paclitaxel, Taxoline) having optimal binding with Lipocalin 2 in comparison with Docetaxel. This data is highly useful for consideration in the design and development of drugs for breast cancer."

Journal • Breast Cancer • Oncology • Solid Tumor • LCN2

A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells. (PubMed, Cancer Lett) - "Taken together, our results demonstrate that the novel taxane, DFV-OTX, can effectively overcome PTX-resistance in MDA-MB-231R cells, wherein the drug resistance was attributed to ABCB1/ABCG2 upregulation and a distinct mode of action in MCF-7R cells. Our results strongly indicate that DFV-OTX is a promising chemotherapeutic agent for the treatment of PTX-resistant cancers."

Journal • Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • ABCB1 • ABCG2

An Efficacy Study Of Ortataxel In Recurrent Glioblastoma (clinicaltrials.gov) - P2; N=45; Completed; Sponsor: Mario Negri Institute for Pharmacological Research; Suspended ➔ Completed

Clinical • Trial completion

Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma. (PubMed, J Neurooncol) - P2; "Overall ortataxel treatment fail to demonstrate a significant activity in recurrent GBM patients. However in a limited number of patients the drug produced a benefit that lasted for a long time."

Clinical • Journal • P2 data